Kyntra Bio Inc. (KYNB)
NASDAQ: KYNBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KYNB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.32M
- EPS (TTM)
- -$4.35
- Dividend yield
- None
- 52-week range
- 1.56 – 10.47
- Day range
- 1.56 – 1.81
- Volume / Avg
- 37.38K / 29.96K
- Beta
- —
- Shares outstanding
- 4.05M
52-week range
KYNB stock today
On Nov 20, KYNB ended the session at $1.56, shedding $0.24 (13.33%), versus the S&P 500's 3.70% decline. At this level, KYNB sits near the bottom of its 52-week range of $1.56 to $10.47: 85.1% below the high, set on Dec 16, 2025 and 0.3% above the low. KYNB is down 82.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 81.5%.
Kyntra Bio has posted a net loss over the last twelve months (EPS of -$4.35), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kyntra Bio
Company profileKyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Thane Wettig
- Headquarters
- San Francisco, CA
- Employees
- 34
- IPO year
- 2014
- Website
- kyntrabio.com
Financial highlights
Full financialsIn fiscal 2025, Kyntra Bio generated $6.4 million in revenue, down 78.3% from fiscal 2024, its first annual decline since 2024. Net income was $183.5 million, for a net margin of 2848.6% versus a median of -160.6% in the prior 5 years. Gross margin was 91.4% (up from 47.5%) and operating margin -712.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.44M | $29.62M | $46.80M | $140.73M | $235.31M |
| Growth | -78.26% | -36.71% | -66.74% | -40.19% | +33.46% |
| Net income | $183.45M | $-47.58M | $-284.23M | $-293.65M | $-290.02M |
| EPS (diluted) | $45.37 | $-11.89 | $-2.92 | $-3.14 | $-3.14 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$39.67+2442.95%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-1.61 vs $-3.66
- Surprise
- +56.01%
KYNB news
All KYNB news- Kyntra Bio (KYNB) Q3 2026 Earnings Call TranscriptNasdaqKYNB, HEI.A
- FibroGen, Inc. Reports Third Quarter 2026 Financial ResultsNasdaqKYNB, ET
- Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Kyntra Bio to Report Third Quarter 2026 Financial ResultsGlobeNewswire
Kyntra Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GTBPGT Biopharma Inc. | 2.96 | -6.92% | $6.33M | vs KYNB |
| ACXPAcurx Pharmaceuticals Inc. | 1.04 | +0.97% | $6.30M | vs KYNB |
| FBLGFibroBiologics Inc. | 0.705 | -15.06% | $6.34M | vs KYNB |
| ADXNAddex Therapeutics Ltd ADR | 3.47 | +2.06% | $6.08M | vs KYNB |
| ENVBEnveric Biosciences Inc. | 1.35 | -4.26% | $6.04M | vs KYNB |
| BFRGBullfrog AI Holdings Inc. | 0.3556 | -8.84% | $6.65M | vs KYNB |
| XCURExicure Inc. | 0.9001 | -12.82% | $5.89M | vs KYNB |
| MTVAMetaVia Inc. | 1.01 | -7.34% | $6.81M | vs KYNB |
Indexes, lists and sector
Kyntra Bio stock FAQ
What is Kyntra Bio's stock price today?
KYNB last traded at $1.56 as of Nov 20, 4:00 PM EST, down 13.33% on the day. Prices are delayed at least 15 minutes.
Does Kyntra Bio pay a dividend?
No. Kyntra Bio does not currently pay a regular cash dividend.
Who is Kyntra Bio's CEO?
Mr. Thane Wettig is the chief executive officer of Kyntra Bio Inc., which has about 34 employees.
Has KYNB ever split its stock?
Yes. The most recent KYNB stock split was a 1-for-25 split on Jun 17, 2025.
What is the KYNB 52-week high?
The 52-week high for KYNB is $10.47 and the 52-week low is $1.56. The stock is currently 85.1% below its high.